Table 2.

Summary of clinical efficacy

AssessmentSorafenib and erlotinib (N = 50) No. of patients (%)
NPR at 6 wk37 (74)
Objective response
    Complete response0 (0)
    Partial response14 (28)
    Stable disease23 (46)
    Progressive disease8 (16)
    Not evaluable5 (10)
Median TTP, mo5.0
    95% CI3.2-6.8
Median survival, mo10.9
    95% CI3.8-18.1